We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMAW
276
DELISTED
Aimfinity Investment Corp I Warrant
AIMAW
$362 ﹤0.01%
18,000
– –
EMCGW
277
DELISTED
Embrace Change Acquisition Corp Warrants
EMCGW
$265 ﹤0.01%
18,000
– –
MKDWW
278
MKDWELL Tech Inc Warrants
MKDWW
$60 ﹤0.01%
+3,270
New +$111
ABT icon
279
Abbott
ABT
$187B
– –
-3,300
Closed -$343K
ADVM
280
DELISTED
Adverum Biotechnologies
ADVM
– –
-11,300
Closed -$77.5K
ALNY icon
281
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-1,850
Closed -$450K
AMPH icon
282
Amphastar Pharmaceuticals
AMPH
$916M
– –
-700
Closed -$28K
ANAB icon
283
CALL
AnaptysBio
ANAB
$1.68B
– –
-1,500
Closed -$37.6K
ANGO icon
284
AngioDynamics
ANGO
$649M
– –
-143,862
Closed -$870K
APLS
285
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-100
Closed -$3.84K
ARQT icon
286
Arcutis Biotherapeutics
ARQT
$3.18B
– –
-1,555
Closed -$14.5K
ATNM icon
287
Actinium Pharmaceuticals
ATNM
$25M
– –
-75,133
Closed -$556K
JBIO
288
CALL
Jade Biosciences
JBIO
$1.34B
– –
-71
Closed -$4.15K
BBIO icon
289
CALL
BridgeBio Pharma
BBIO
$16.5B
– –
-3,700
Closed -$93.7K
BBIO icon
290
PUT
BridgeBio Pharma
BBIO
$16.5B
– –
-1,200
Closed -$30.4K
BLUE
291
DELISTED
bluebird bio
BLUE
– –
-300
Closed -$5.91K
CAPR icon
292
PUT
Capricor Therapeutics
CAPR
$237M
– –
-20,400
Closed -$97.3K
CATX icon
293
Perspective Therapeutics
CATX
$342M
– –
-69,985
Closed -$698K
CCOI icon
294
Cogent Communications
CCOI
$508M
– –
-4,000
Closed -$226K
CTVA icon
295
Corteva
CTVA
$51.3B
– –
-11,400
Closed -$615K
ECDAW
296
DELISTED
ECD Automotive Design Warrant
ECDAW
– –
-32,596
Closed -$652
ELEV
297
DELISTED
Elevation Oncology
ELEV
– –
-84,927
Closed -$229K
EQ icon
298
CALL
Equillium
EQ
$133M
– –
-8,800
Closed -$6.1K
ERAS icon
299
Erasca
ERAS
$6.39B
– –
-3,100
Closed -$7.32K
ETON icon
300
Eton Pharmaceutcials
ETON
$1.22B
– –
-1,200
Closed -$3.95K
10 11
12
13 14

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.